Drug companies told to do more to tackle 'superbug' crisis

LONDON (Reuters) - Drugmakers' response to the threat posed by "superbugs" remains patchy even after years of warnings, according to the first analysis of individual companies' efforts to tackle the antibiotic resistance crisis.